Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 2
1995 21
1996 21
1997 23
1998 47
1999 75
2000 78
2001 75
2002 103
2003 89
2004 109
2005 134
2006 105
2007 125
2008 106
2009 104
2010 101
2011 95
2012 98
2013 96
2014 69
2015 48
2016 40
2017 43
2018 41
2019 34
2020 28
2021 34
2022 23
2023 24
2024 36
2025 33
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,955 results

Results by year

Filters applied: . Clear all
Page 1
Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial.
Pereira F, Magagnoli J, Ambati M, Fernandes de Oliveira T, Estevão de Oliveira JA, Pesquero VO, Ribeiro LZ, Kondo Kuroiwa DA, Malerbi FK, Dib SA, Moraes NB, Farah ME, Rodrigues EB, Ambati J. Pereira F, et al. Med. 2025 Sep 12;6(9):100747. doi: 10.1016/j.medj.2025.100747. Epub 2025 May 27. Med. 2025. PMID: 40436012 Free PMC article. Clinical Trial.

FINDINGS: At 4 weeks, BCVA improved 9.8 letters with lamivudine and decreased 1.8 letters with placebo (p < 0.001). At 8 weeks, BCVA improved 16.9 letters with lamivudine and bevacizumab and 5.3 letters with placebo and bevacizumab (p < 0.001). Lamivudine

…

FINDINGS: At 4 weeks, BCVA improved 9.8 letters with lamivudine and decreased 1.8 letters with placebo (p < 0.001). At 8 weeks, BC

…
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.
Cordova E, Hernandez Rendon J, Mingrone V, Martin P, Arevalo Calderon G, Seleme S, Ballivian J, Porteiro N. Cordova E, et al. Lancet HIV. 2025 Feb;12(2):e95-e104. doi: 10.1016/S2352-3018(24)00294-7. Epub 2025 Jan 15. Lancet HIV. 2025. PMID: 39826566 Clinical Trial.
BACKGROUND: Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without baseline resistance testing raises concerns about the potential presence of pretreatment lamivudine resistance. ...We randomly assigned (1 …
BACKGROUND: Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without basel …
Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis.
Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Chan HL, et al. J Viral Hepat. 2012 Oct;19(10):732-43. doi: 10.1111/j.1365-2893.2012.01600.x. Epub 2012 Mar 15. J Viral Hepat. 2012. PMID: 22967105 Clinical Trial.
We studied the safety and efficacy of telbivudine and lamivudine in such patients. This noninferiority, double-blind trial randomized 232 treatment-naive patients with decompensated HBV (1:1) in 80 academic hospitals to receive once-daily telbivudine 600 mg or lamivudin …
We studied the safety and efficacy of telbivudine and lamivudine in such patients. This noninferiority, double-blind trial randomized …
Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B.
Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Ghany MG, et al. Aliment Pharmacol Ther. 2012 May;35(9):1027-35. doi: 10.1111/j.1365-2036.2012.05059.x. Epub 2012 Mar 26. Aliment Pharmacol Ther. 2012. PMID: 22449251 Free PMC article. Clinical Trial.
METHODS: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks. ...CONCLUSIONS: Extended combination therapy with lamivu …
METHODS: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 …
Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.
De Miguel R, de Lagarde Sebastian M, Blanco Arévalo JL, Pinto-Martinez A, Montejano R, Gutiérrez Liarte A, Navarro-Soler R, Cañas-Ruano E, Inciarte A, Martin-Carbonero L, Imaz A, Hernández Gutiérrez C, Ocampo A, Gil Divasson P, Delgado R, Pulido F, Arribas JR. De Miguel R, et al. Clin Infect Dis. 2025 Oct 6;81(3):491-498. doi: 10.1093/cid/ciaf100. Clin Infect Dis. 2025. PMID: 40052565 Free article. Clinical Trial.
BACKGROUND: We investigated the efficacy of dolutegravir/lamivudine for maintenance treatment for people with human immunodeficiency virus (HIV, PWH) and previous lamivudine resistance. ...Also, 90.1% participants (109/121) had a VL <50 copies/mL (95% CI: 83.3%-9 …
BACKGROUND: We investigated the efficacy of dolutegravir/lamivudine for maintenance treatment for people with human immunodeficiency …
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial.
de Lazzari E, Di Gregorio S, Rojas J, Curran A, Domingo P, Negredo E, Tiraboschi J, Gonzalez-Cordon A, Torres B, Sempere A, Inciarte A, Gatell JM, Blanco JL, Martinez E; DOLAM study group. de Lazzari E, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2226-2233. doi: 10.1093/jac/dkaf192. J Antimicrob Chemother. 2025. PMID: 40556520 Free article. Clinical Trial.
BACKGROUND: Switching to dolutegravir plus lamivudine has been associated with weight gain. We aimed to assess factors associated with weight gain and changes in body composition in people with HIV switching to dolutegravir plus lamivudine in the DOLAM trial (EudraC …
BACKGROUND: Switching to dolutegravir plus lamivudine has been associated with weight gain. We aimed to assess factors associated wit …
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
De Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, Garcia-Alvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadiñanos J, Mayoral M, Castro JM, Moreno V, Martin-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR; ART-PRO, PI16/00837-PI16/00678 study group. De Miguel R, et al. EBioMedicine. 2020 May;55:102779. doi: 10.1016/j.ebiom.2020.102779. Epub 2020 May 11. EBioMedicine. 2020. PMID: 32408111 Free PMC article. Clinical Trial.
Ten participants (4 in the group with historical lamivudine resistance) had a transient viral rebound, all resuppressed on dolutegravir plus lamivudine. ...INTERPRETATION: In this pilot trial, dolutegravir plus lamivudine was effective in maintaining virologi …
Ten participants (4 in the group with historical lamivudine resistance) had a transient viral rebound, all resuppressed on dolutegrav …
Clinical trial of lamivudine in children with chronic hepatitis B.
Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric Lamivudine Investigator Group. Jonas MM, et al. N Engl J Med. 2002 May 30;346(22):1706-13. doi: 10.1056/NEJMoa012452. N Engl J Med. 2002. PMID: 12037150 Free article. Clinical Trial.
BACKGROUND: Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with hepatitis B virus (HBV) in children. ...RESULTS: Of the 403 children screened, …
BACKGROUND: Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability o …
Bioequivalence and Pharmacokinetics Study of Two Zidovudine/Lamivudine Tablets in Chinese Healthy Volunteers.
Huang X, Wang G, Huang J, Liang W, Guan H, Liu H, Deng Y, You Y, Zhang B. Huang X, et al. Clin Pharmacol Drug Dev. 2024 Jan;13(1):14-20. doi: 10.1002/cpdd.1335. Epub 2023 Nov 20. Clin Pharmacol Drug Dev. 2024. PMID: 37986709 Clinical Trial.
Zidovudine/lamivudine tablets are nucleoside reverse transcriptase inhibitors that are used to treat human immunodeficiency virus. ...The plasma concentrations of zidovudine and lamivudine were determined by a validated ultra-performance liquid chromatography-tandem …
Zidovudine/lamivudine tablets are nucleoside reverse transcriptase inhibitors that are used to treat human immunodeficiency virus. .. …
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
Chandasana H, Singh R, Adkison K, Ait-Khaled M, Pene Dumitrescu T. Chandasana H, et al. Antimicrob Agents Chemother. 2024 May 2;68(5):e0150423. doi: 10.1128/aac.01504-23. Epub 2024 Apr 8. Antimicrob Agents Chemother. 2024. PMID: 38587380 Free PMC article. Clinical Trial.
A fixed-dose combination (FDC) of 50 mg dolutegravir and 300 mg lamivudine is indicated for the treatment of HIV-1 infection. This analysis aimed to characterize the population pharmacokinetics (PK) of dolutegravir and lamivudine based on data from a phase 3 study ( …
A fixed-dose combination (FDC) of 50 mg dolutegravir and 300 mg lamivudine is indicated for the treatment of HIV-1 infection. This an …
1,955 results